Background. Antimicrobial stewardship programs are advised to measure and risk-adjust antimicrobial use to facilitate interhospital comparisons, a process called benchmarking. The purpose of this investigation was to evaluate a new benchmarking strategy for antibacterials.
The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America 2007 guidelines to develop institutional antimicrobial stewardship programs (ASPs) recommend hospitals measure their antimicrobial drug use so they may compare their use with others, recognizing the challenges of interhospital comparisons and the potential need for risk adjustment [1] . Risk adjustment is intended to control for interhospital differences in case mix that otherwise confound comparisons. Previous interhospital comparisons of aggregate antimicrobial drug use have been descriptive [2] [3] [4] [5] [6] [7] [8] [9] [10] or used regression models to identify predictors of use, such as case mix index, bed size, and number of transplant patients [11] [12] [13] . However, regression model reliability may be compromised by coding errors and exclusion of important predictors, and regression models do not readily identify specific areas for improvement.
Comparison of health care process measures or outcomes to internal or external standards is often called ''benchmarking'' [14] . We refer here to comparisons of antibacterial drug use as benchmarking although no external gold standard for antibiotic use exists [15] . The purpose of the present investigation was to develop and evaluate new methods to measure and risk-adjust systemic antibacterial drug use in adult inpatients and to develop clinically useful benchmarks.
METHODS

Data Source
The University HealthSystem Consortium (UHC; https://www. uhc.edu) is an alliance of 103 academic medical centers (AMCs) and affiliated hospitals. A subset of AMCs subscribe to the Clinical Resource Manager, which extracts data on medication use from charge transaction masters and inpatient billing files. AMCs that subscribed to Clinical Resource Manager during calendar year 2009 were the data source for this investigation as previously described [10] .
Hospital-Wide Antibacterial Drug Use
Patient-level usage in adult inpatients for 52 systemic antibacterial drugs in 70 AMCs was aggregated and reported as days of therapy (DOT) per 1000 patient-days as previously described [10] . The complete list of agents is available online. Any dose of an antibiotic received during a 24-hour period (beginning at midnight) represents 1 DOT. For example, parenteral piperacillin/tazobactam, vancomycin, and ciprofloxacin administered on the first day of therapy contribute 1 DOT for each drug (a total of 3 DOTs).
We also evaluated an alternative method of measuring use, the length of therapy (LOT). The LOT has also been called the ''treatment period'' [5] and ''patient-days receiving antimicrobials'' [16] . The LOT is the number of days that a patient receives systemic antibacterial drug(s), irrespective of the number of different drugs. In the example above, therapy with 3 different drugs on the first day is counted as 1 LOT. Thus the LOT will be less than or equivalent to the DOT measure. Unlike the DOT, the LOT cannot be used to compare use of specific drugs. However, the LOT provides a more accurate assessment of the true duration of antibacterial therapy. Furthermore, the DOT/LOT ratio may be a useful benchmarking proxy for the frequency of combination antibacterial use versus monotherapy. Therefore, the LOT provides complementary information to the DOT measure.
Grouping of Patients by Clinical Service Line
Each adult patient was assigned to 1 of 745 Medicare Severity Diagnosis Related Groups (MS-DRGs) by the Centers for Medicare and Medicaid Services (CMS) MS-DRG Grouper software at discharge (http://www.ntis.gov/products/grouper.aspx; accessed on 4 August 2011). The software utilizes diagnoses, procedures, and demographic information in the billing abstract to classify patients into diagnosis-related groups expected to have similar hospital resource use [17] . At the UHC, cases were clustered into 35 clinical service lines (CSLs) based upon similar MSDRGs. Examples are provided in the Table 1 ; the complete MS-DRG composition of each CSL is available online. Some AMCs did not have patients assigned to 1 or more CSLs (Table 1) . Within each CSL the following data were available: number of adults discharged during the study period, total patient-days, number of patients who received antibacterial drug therapy, specific antibacterial drugs, total LOT and DOT, and mean DOT and LOT per discharge.
Expected Antibacterial Drug Use by Indirect Standardization
Indirect standardization [18] was used to derive expected antibacterial drug use within each CSL and hospital-wide as follows. The overall mean DOT and LOT per discharge for patients who received antibacterial therapy in each CSL were determined for all 70 hospitals. The number of patients in each CSL at each hospital who received antibacterial therapy was identified, and the expected LOT and DOT were estimated from the product of the number of patients and the mean LOT and DOT per discharge in each CSL. The expected (E) values were then compared with the observed (O) values of DOT and LOT per 1000 patientdays for each CSL, and O/E ratios were determined. The expected hospital-wide total antibacterial drug use was the sum of expected values for total LOT and DOT in each CSL and was compared with observed hospital-wide use.
Statistical Analysis
The indirectly standardized rates for hospital-wide DOT and LOT per 1000 patient-days were calculated as the product of the O/E ratio and the crude antibiotic use rate in the reference population (the mean of 70 hospitals). The z scores for O/E ratios of hospital-wide DOT and LOT per 1000 patient-days were calculated by subtracting the indirectly standardized rates for each hospital from the crude rate, divided by the standard deviation in the reference population. Because this was not a hypothesis-testing investigation, we used the 90% confidence interval (CI) for z scores to identify the extreme 5% of AMCs on both sides of the distribution. A z score exceeding 11.64 or less than 21.64 identified AMCs where the O/E ratio for use was above or below the 90% CI, respectively.
RESULTS
Hospital Demographics
Mean bed size for the 70 AMC hospitals was 544 (range, 185-1156) and the number of adults discharged from all hospitals was 1 791 180 (mean, 25 588; range, 4103-54 303), representing 9 820 983 total adult patient-days (mean, 140 300; range, 14 377-299 705). The mean CMS case mix index for adult patients was 1.62 (hospital range, 1.06-1.99). The geographic distribution for hospitals was mid-Atlantic states (13) , midcontinent (14) , midwestern (16), New England (7), southeastern (11) , and western (9) .
Antibacterial Drug Use
Hospital-Wide Aggregated Antibacterial Drug Use The observed mean 6 SD total antibacterial drug use was 839 6 106 (median, 809; range, 594-1109) DOTs per 1000 patient-days ( Figure 1 ). The mean LOT was 536 6 53.0 (median, 529; range, 427-684) LOT per 1000 patient-days. A strong [12] .
Observed Versus Expected Use
The O/E ratios for hospital-wide drug use are seen in Figure 2 . For example, the observed use for hospital 70 (Figure 1 ) was 1101 DOTs per 1000 patient-days and the expected value was 763 DOTs per 1000 patient-days; the O/E ratio of 1.44 is plotted in Figure 2 . Observed use in hospital 3 was 617 DOTs per 1000 patient-days and the expected use was 851 DOTs per 1000 patient-days; the O/E ratio of 0.73 is plotted. The O/E ratio for 11 hospitals fell outside the 90% CI as measured by DOT or LOT per 1000 patient-days, or both (in Figure 2) . Expressing aggregate drug use as DOT or LOT per 1000 patient-days does not clearly convey the components that determine use, specifically the product of the number of treated patients and the mean DOT or LOT per discharge. The mean of 70 hospitals for the hospital-wide proportion of adult patients who received at least 1 dose of an antibacterial drug was 63.7% (range, 49.6%-76.0%). The mean hospital-wide DOT and LOT per discharge among patients who received an antibiotic were 7.2 6 1.2 days (range, 3.7-10.2) and 4.6 6 0.6 days (range, 2.7-6.2), respectively. Observed Antibacterial Use by CSL The proportion of patients who received at least 1 dose of an antibacterial drug differed substantially across CSLs ( Table 1) . The smallest proportions included psychiatry (14%) and substance abuse (20%) patients and the largest included bone marrow and solid organ transplant (.96%) and ventilator support patients (99%).
The mean DOT and LOT per discharge also depended upon CSL (Table 1) . Patients in the psychiatry CSL had a relatively short mean DOT per discharge (5.8 days) and a similar mean LOT per discharge (5.2 days). The DOT/LOT ratio of 1.10 suggests that patients in the psychiatry CSL usually received monotherapy for a relatively short period of time. In contrast, nearly all patients in the ventilator support CSL received antibacterial therapy (mean DOT and LOT per discharge, 39.4 and 21.5 days, respectively). The DOT/LOT ratio of 1.83 indicates that combination antibacterial therapy is common.
Frequency distributions for the proportion of patients who received antibacterial therapy in each hospital and the LOT and DOT per discharge are shown for 3 representative CSLs ( Figures 3  and 4, respectively) . These are direct hospital-to-hospital usage comparisons. Large variability occurred in the proportion of patients who received antibacterial drugs in some CSLs such as obstetrics and psychiatry, and very little variability in others such as ventilator support (Figure 3 ). On the other hand, variability in the LOT per discharge was low in the obstetrics CSL, moderate in psychiatry, and greatest in the ventilator support CSL (Figure 4) . The frequency distribution for the DOT/LOT ratios for the orthopedics, general medicine, and ventilator support CSLs are shown in Figure 5 . The orthopedics CSL used combination antibacterial therapy the least, whereas the ventilator support CSL used combination antibacterial therapy the most. Figure 6 illustrates benchmarking of the O/E ratio for each CSL in 3 AMCs with different overall patterns of antibacterial drug use. In Figure 6A , total observed use is much greater than expected use and the O/E ratio in most CSLs exceeds unity. In Figure 6B the O/E ratio for total use is near unity, but there is substantial variability in the O/E ratios across CSLs. In Figure 6C the O/E ratio for total use and for most CSLs is less than unity.
Comparison of Observed and Expected Use by CSL
Measurement of antibacterial drug use by DOT and LOT per 1000 patient-days does not address the number of patients treated, a frequent criticism of aggregate measures of drug use [5, 6] . For example, patients in the lung transplant CSL have very high antibacterial drug use as measured by LOT and DOT per discharge and by DOT per 1000 patient-days, but this CSL represents relatively few patients (Table 1) . Consequently a ''benchmarking report'' provided to a hospital, such as that shown in Figure 6 , should include the number of patients in each CSL to identify areas for investigation with the greatest potential impact.
DISCUSSION
Benchmarking has been applied to many infectious diseases including hospital-acquired infections [19, 20] , ventilator-associated pneumonia [21] , and community-acquired pneumonia [22] . The rationale for benchmarking hospital antimicrobial drug use is analogous to that for health care-associated infections: to identify outliers-both high and low-so that bestpractice strategies can be identified and implemented to improve patient care [23] . It has only recently become possible to measure antimicrobial drug use in networks of hospitals, and benchmarking methods are in their infancy [24] .
We believe the current investigation has a number of advantages that merit development. First, the most appropriate metric for measuring antibacterial drug use for benchmarking purposes remains a matter of considerable debate, both in Europe [3, 5, 6] and North America [25] . The present investigation risk-adjusted antibacterial drug use in adults using DOT instead of the more Figures 1 and 2 because, for example, a low observed use in Figure 1 may also have a low expected use and an O/E ratio of near 1.) AMCs with O/E ratios lower than the 90% confidence interval (measured by DOT, LOT, or both) included hospitalcommon defined daily dose (DDD). We [25, 26] and others [3, 5, 6] have argued that DDD methods to measure antibacterial consumption have a serious limitation when used for benchmarking; total DDDs reflect not only volume of use but also formulary composition. Computerization of pharmacy administration data in the United States is making possible direct measurement of the DOT, the parameter the DDD is intended to estimate. Furthermore, the US National Healthcare Safety Network measures hospital antibacterial use by DOT (http://www.cdc.gov/nhsn/psc_ma.html). Second, we have described a newer measure of use, the length of treatment, that offers an additional benchmarking perspective to the DOT metric. The most obvious advantage is that the mean LOT per discharge is a measure of the true duration of (Figure 3) , the length of therapy (LOT) per discharge determines the total LOT for each CSL. These data can be reported to each hospital for the 35 CSLs and this may allow antimicrobial stewardship programs to identify intervention strategies for high-volume antibacterial drug use within CSLs when observed use exceeds expected use.
antimicrobial therapy at both the patient level and when grouped by CSLs as described. For example, the mean LOT for patients in the ventilator support CSL was 21 days. In contrast, the mean DOT of 42 days does not measure therapy duration but rather the summation of use of different drugs. The LOT measure may prove useful for benchmarking in 2 areas. First, a hospital can directly compare its mean LOT per discharge to other hospitals for a given CSL (Figure 4 ). This comparison and comparison of the proportion of treated patients in a CSL ( Figure 5 ) are direct interhospital comparisons, risk-adjusted for patient mix. A second application is that the DOT/LOT ratio focuses on the use of combination therapy as a benchmark ( Figure 6 ). For example, a hospital that uses a quinolone and clindamycin for treatment of diabetic foot ulcer, versus piperacillin/tazobactam, will have double DOT values even though the LOT values may be the same. This may be useful to know if a hospital wishes to reduce its total DOT. The need for combination antibacterial chemotherapy, including for severely ill patients, has increasingly been challenged [27, 28] , and ASP activities often include ''streamlining'' strategies to reduce the number of drugs [1] . Consequently the mean LOT per discharge and DOT/LOT ratios may become useful metrics to help identify potential interventions.
Third, the use of MS-DRG to cluster adult patients into CSLs to assess antibiotic use makes intuitive sense and has been used previously to develop risk-adjusted indices for assessing the quality of inpatient care [29] . A similar approach was used to develop benchmarks for antimicrobial use in different hospital wards based upon severity of illness measured by case mix index [11] . Our method not only identifies hospitals where the hospitalwide aggregate use deviates from predicted use but it also identifies the specific CSLs responsible and the characteristics that describe drug use, information that is not available from regression models. With this information an ASP may be able to perform drug utilization evaluations (DUEs) and identify areas for intervention such as excessive durations of therapy, excessive proportion of patients treated, or excessive use of combination therapies.
Fourth, it would now appear possible to test the ''benchmarking hypothesis''; specifically, will hospitals implement interventions designed to change antibacterial drug use in response to riskadjusted comparative usage data as described, and will this be accompanied by measurable clinical outcomes? As a quality indicator, antibacterial drug use is a process variable and not an outcome [15] . If benchmarking antimicrobial drug use is eventually shown to result in changes in drug use, the desirable clinical outcomes could include clinical response, a reduction in bacterial resistance including infections caused by Clostridium difficile, economic savings, and fewer adverse events [1, 15] . The only relevant investigation we are aware of is a comparison of vancomycin use in intensive care units by the Centers for Disease Control and Prevention's Project ICARE [30] . Additional research is needed to determine if benchmarking as described here will result in these desirable outcomes. (Figure 2 ), the mean DOT and LOT per discharge (Figure 3) , the greater use of combination therapy will increase the DOT/LOT ratio and overall drug consumption. A hospital in the right tail of the distribution may find it useful to examine the frequency of combination antibacterial therapy for high-volume CSLs and to develop strategies to ''streamline'' treatment regimens. Finally, the use of CSLs to risk-adjust and benchmark antibacterial drug use may result in continuous quality improvements for the entire network. AMCs where the hospital-wide O/E ratio is near unity does not mean that use is appropriate in all CSLs. Some CSLs will likely have ratios exceeding unity in 1 or more of the 35 CSLs as illustrated in Figure 6B and efforts to improve use in these CSLs may result in lower total antibacterial use over time. This will constantly revise the ''expected'' antibacterial drug use for the entire network downward because the mean use for all hospitals is the driver for the expected use at individual hospitals in this report. Although benchmarking cannot measure the appropriateness of therapy, the group of hospitals where the O/E ratio was ,1 across most CSLs, such as in Figure 6C , may represent a subset of hospitals where antibacterial drug use is the most appropriate. Additional research is needed to identify characteristics of these hospitals, including the contribution of ASP activities.
This new method to risk-adjust and benchmark antibacterial drug use has limitations. First, we cannot be certain that the patient case mix within each CSLs across hospitals is homogeneous. Some CSLs include only 1 or 2 MS-DRGs, such as lung (DRG 1) and liver transplants (DRGs 5 and 6), whereas the general medicine CSL contains 113 MS-DRGs. Additionally, socioeconomic status was not measured and this may add variability in drug use if, for example, some patients are discharged earlier to complete therapy at home. The perspective of this investigation was the hospital, and not society or patients. Additional research to evaluate heterogeneity across CSLs is warranted. Second, we are unable to assess appropriateness of antimicrobial therapy. This benchmarking method is likely to be most useful to ASPs by providing direction for follow-up DUE, although it may prove difficult to identify specific patients for DUE because patients within a CSL are not necessarily confined to a specific hospital location. Third, administrative databases have the potential for coding errors, and additional validation is warranted [31] . Also, we have not described use of specific antibacterial drugs, and additional efforts to validate drug usage and to separate prophylaxis from therapeutic use may be warranted. Fourth, the relative merits of direct versus indirect standardization are being debated [18, 24, 32] . A recent report from Finland used indirect standardization to case-mix adjust antibacterial drug use in 30 acute care hospitals [33] . Finally, patient case mix is different in community hospitals than in many AMCs, although the methods described should be applicable to non-AMC hospitals. Additional research including refinement of this method and strategies for implementation and evaluation appear warranted.
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